“Moderna is committed to making as many changes to our vaccine as necessary, until the pandemic is under control”, according to the CEO of the American biotech.
Reading time : 1 min.
The American biotech company Moderna announced on Wednesday February 24 that a modified version of its vaccine against Covid-19, developed specifically against the South African variant, was ready to be tested on humans in clinical trials. “Moderna has sent doses of its specific candidate vaccine against the variant (…) first identified in South Africa to the NIH [Instituts nationaux de santé américains, NDLR] for a clinical study “, the company said in a statement.
“In our fight against Covid-19, we must be vigilant and proactive about the new variants of SARS-CoV-2 that are emerging”, added Stéphane Bancel, boss of Moderna. “Moderna is committed to making as many changes to our vaccine as necessary, until the pandemic is under control.”
The US Medicines Agency has indicated that manufacturers will not have to go through the long authorization process again for already approved vaccines if they are changed to combat the emergence of new variants of the coronavirus. which should greatly shorten the process.